EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune checkpoint CD161 / LLT1 ‐associated immunological landscape and diagnostic value in oral squamous cell carcinoma

Xinyang Hu iD, Yuexin Dong, Shixin Xie, Yuxian Song, Chenhang Yu, Yijia He, Zhiyong Wang, Qingang Hu, Yanhong Ni, Liang Ding iD

The Journal of Pathology: Clinical Research · 2024

DOI: 10.1002/cjp2.353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2024. Verfasst von Xinyang Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, PR China. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Nanjing Medical Science and Technology Development Foundation, Nanjing Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An active host adaptive response is characterized by the existence of programmed cell death protein 1 (PD‐1) + /IFN‐γ + cytotoxic T cells and IFN‐γ‐induced PD‐L1 + tumor cells (TCs), which predicts high response rate to anti‐PD‐1/L1 therapy. Recently, CD161 and its ligand LLT1 (CLEC2D) have been identified as an emerging checkpoint for immunotherapy. Clarifying its heterogeneous clinical expression pattern and its immune landscape is a prerequisite for maximizing the response rate of CD161 blockade therapy in a specific population of oral squamous cell carcinoma (OSCC) patients. Here, we investigated the expression pattern of CD161/LLT1 and its association with major immunocytes (T cells, B cells, NK cells, and macrophages) by multiplex immunofluorescence, immunohistochemistry, and flow cytometry in 109 OSCC tissues and 102 peripheral blood samples. TCs showed higher LLT1 levels than tumor infiltrating lymphocytes (TILs), whereas CD161 was highly expressed in CD8 + T cells at the tumor front, which was decreased in paracancerous tissue. High expression of TC‐derived LLT1 (LLT1 TC ) conferred poor clinical outcomes, whereas higher CD161 + and LLT1 + TILs were associated with better prognosis. Meanwhile, patients with high LLT1 TC showed a decreased ratio of CD8 + /Foxp3 + T cells in situ , but CD161 + TILs correlated with more peripheral CD3 + T cells. Interestingly, treatment of OSCC patients with nivolumab (anti‐PD‐1) could restore tumoral CD161/LLT1 signal. Furthermore, an OSCC subgroup characterized by high LLT1 + TCs and low CD161 + CD8 + T cells showed fewer peripheral T cells and a higher risk of lymph node metastasis, leading to a shorter 5‐year survival time (29%). More LLT1 TC at the invasive front was another risk characteristic of exhausted T cells. In conclusion, in view of this heterogeneity, the LLT1/CD161 distribution pattern should be determined before CD161‐based immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsHumansCD8-Positive T-LymphocytesSquamous Cell Carcinoma of Head and NeckReceptors, Cell SurfaceLectins, C-TypeNK Cell Lectin-Like Receptor Subfamily B

Stichwörter der Autor:innen

CD161Foxp3LLT1OSCCPD-1PD-L1T cellsimmune checkpointimmune checkpoint inhibitorsimmunotherapyoral squamous cell carcinoma

Substanzen

CLEC2D protein, humanReceptors, Cell SurfaceLectins, C-TypeKLRB1 protein, humanNK Cell Lectin-Like Receptor Subfamily B

Autor:innen und Institutionen

  • Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, PR China.
  • Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, PR China.

ORCID-Profile: Xinyang Hu, Liang Ding

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Nanjing Medical Science and Technology Development Foundation, Nanjing Department of Health

Zitieren

APA

Hu, X., Dong, Y., Xie, S., Song, Y., Yu, C., He, Y., Wang, Z., Hu, Q., Ni, Y., & Ding, L. (2024). Immune checkpoint CD161 / LLT1 ‐associated immunological landscape and diagnostic value in oral squamous cell carcinoma. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/cjp2.353

Vancouver

Hu X, Dong Y, Xie S, Song Y, Yu C, He Y, et al. Immune checkpoint CD161 / LLT1 ‐associated immunological landscape and diagnostic value in oral squamous cell carcinoma. The Journal of Pathology: Clinical Research. 2024. doi:10.1002/cjp2.353

BibTeX
@article{Hu2024,
  author = {Hu, Xinyang and Dong, Yuexin and Xie, Shixin and Song, Yuxian and Yu, Chenhang and He, Yijia and Wang, Zhiyong and Hu, Qingang and Ni, Yanhong and Ding, Liang},
  title = {Immune checkpoint CD161 / LLT1 ‐associated immunological landscape and diagnostic value in oral squamous cell carcinoma},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2024},
  doi = {10.1002/cjp2.353}
}
Kostenlos starten →